Altered intercellular communication

Your cells are in constant chemical conversation, and with age that conversation fills with static: worn-out cells broadcast inflammatory noise, the physical links between neighbours degrade, and the blood itself carries pro-aging signals. The description is well established, mostly from cell and animal work; no therapy has been shown to reverse it in a healthy person, and the everyday levers with trial evidence shift the circulating signals only modestly.

Exercise regularly and eat a Mediterranean-style diet: in trials they modestly lower some blood markers of inflammation. A regular sleep schedule is sensible too, though the human evidence for it is thinner. Don't pay for plasma exchange, young-plasma infusions or senolytic drugs to reset your signalling; all are experimental, and hormone treatment belongs only where a doctor finds a clinical need.

How aging becomes a whole-body problem

Altered intercellular communication is the tenth of the twelve hallmarks of aging and one of the four integrative hallmarks, the system-wide consequences that emerge once damage has built up inside cells. It sits alongside stem-cell exhaustion, chronic inflammation and dysbiosis.[1] Where the primary hallmarks describe damage inside cells, this one describes the breakdown of signalling between them, which is how local damage turns into body-wide decline.

A useful way to picture it is signal-to-noise: healthy tissue keeps its chemical messages clear, while aged tissue fills with background clutter that drowns out the cues cells depend on. One research group has measured a version of this directly, finding that the proteins made in older tissue become noisier as well as more abundant with age.[2]

That signalling degrades with age is not in doubt. The evidence that it drives aging is weaker than for most hallmarks, because it is largely correlative and the most dramatic experiments are in animals. A hallmark is supposed to pass three tests: it appears during normal aging, worsening it accelerates aging, and treating it slows aging. This one meets the third test least convincingly.[3]

Senescent cells are the loudest source of noise

The single largest contributor is the senescent cell: a worn-out cell that has stopped dividing but refuses to die. It stays metabolically active and keeps secreting a pro-inflammatory mix, the senescence-associated secretory phenotype (SASP), made of inflammatory signalling proteins, chemical attractants for immune cells and tissue-degrading enzymes.[4]

That makes it a communication problem in two ways, both shown so far in cells and animals. SASP factors push neighbouring healthy cells into "bystander" senescence; in mice, transplanting a relatively small number of senescent cells was enough to spread senescence into the host's own tissues and impair physical function.[5] And senescent cells package part of their cargo into extracellular vesicles, tiny membrane-wrapped parcels that can push nearby and, in cell and mouse experiments, more distant cells toward senescence. Reviews propose this may spread the damage through the body, but some vesicles appear to lessen senescence instead, and the spread has not been shown directly in human tissue.[6]

The sustained output of these signals produces inflammaging, the chronic, low-grade inflammation of aged tissue. Senescent cells and the drugs aimed at them are covered under cellular senescence; this article follows the other channels.

Each of these channels is well described in cell and animal work; none rests on a human outcome trial.

Gap junctions are channels between neighbouring cells that let small signalling molecules pass directly from one to the next. The age-related failure is easy to state backwards: the channels are still there, but they stop opening on cue. In bone-forming cells taken from old rats and grown in a dish, the channel proteins held steady, yet the cells failed to step up communication when stimulated by parathyroid hormone. The authors suggest this may contribute to age-related bone loss, but no bone was measured in living animals, so that link is a hypothesis.[7]

Tunneling nanotubes are long, thin bridges that let cells shuttle cargo, even whole mitochondria, over surprising distances, sometimes to rescue a damaged neighbour. In lab studies, inflammation, oxidative stress and injury make more of them form, and in cell culture they can carry toxic protein clumps such as tau and alpha-synuclein from one neuron to the next.[8] Whether that happens in the living human brain, and adds to the spread of Alzheimer's and Parkinson's disease, has not been shown; the structures are fragile and have no specific marker.[9]

The scaffold around cells stiffens. The collagen and elastin fibres that cells sit in last for decades and build up chemical cross-links and sugar-driven damage, making tissue progressively rigid. Cells sense that rigidity, and one hypothesis holds that a stiff matrix pushes them toward scarring and senescence.[10] Reversing it has proved hard: alagebrium, a drug designed to break sugar-driven cross-links, did not soften arteries in a year-long trial of 48 healthy, inactive adults around 70,[11] nor improve exercise capacity in 102 people with heart failure and a weakened heart pump.[12] Vitamin C and dietary protein are needed to build collagen in the first place, but there is no good evidence that getting more than enough undoes the cross-linking. The best human signal for less-stiff arteries comes from regular aerobic exercise four to five days a week from middle age onward, and even that rests largely on comparisons between people rather than trials.[13]

Old blood suppresses young tissue, in mice

The most striking evidence that aging is partly carried in the blood comes from parabiosis: surgically joining the circulations of a young and an old mouse. The old animal's tissues partially rejuvenate, at some expense to the young one. A cleaner version that only exchanges blood shows which direction is stronger: in many tissues, old blood's harm to young tissue outweighs young blood's benefit to old tissue, and injury makes it worse.[14] Old blood carries a recognisable set of pro-inflammatory proteins; in mice, several of them reduce the birth of new neurons and impair memory.[15]

Two lifespan studies disagree. In the more recent one, old female mice joined to young partners for three months lived a median of about six weeks longer.[16] An earlier study by a second lab found only a small, non-significant gain in old animals, and its young partners died sooner.[17]

People cannot be joined to a younger partner. The closest human tests remove plasma, with or without replacing it; they are mostly small, mostly track biomarkers rather than health, and point in different directions (see the therapies section below). The same circulating mix of immune and hormonal signals is also where chronic stress and isolation act on the body, covered under purpose and stress.

The brain's hormonal control centre drifts

The hypothalamus, the brain region that runs the hormone system, ages in a way that ripples outward. In mice, local inflammation in the hypothalamus suppresses gonadotropin-releasing hormone (GnRH), the signal at the top of the reproductive hormone chain, and blocking that inflammation slowed aging and lengthened life. The fall in GnRH went along with fewer new neurons and with thinner skin, weaker muscle and bone loss, and giving GnRH to old mice lessened these changes. GnRH itself was never tested for an effect on lifespan, and it has not been tested as an aging treatment in people.[18] In humans, the GnRH that drives the reproductive hormones comes from a strikingly small group of about 2,000 cells in the hypothalamus; people also carry a much larger set of 150,000–200,000 GnRH-making cells elsewhere in the brain, mostly in the basal ganglia, whose role is not yet understood.[19]

The same drift reaches other hormone systems. With age, the pituitary's thyroid-stimulating signal (TSH) tends to creep up and the active thyroid hormone (T3) tends to fall, while the main circulating thyroid hormone (T4) usually holds steady; the daily cortisol rhythm flattens because evening cortisol stays high. How much of this is aging itself rather than illness, eating less or medication, and whether it harms health, is unsettled.[20]

Hormone treatment has a role only when there is a clinical reason: menopausal hormone therapy in the right window, testosterone therapy for symptomatic deficiency, and thyroid management. It is not an anti-aging measure for someone with normal levels, and the age-related drift itself is not a target: in a placebo-controlled trial of 737 adults aged 65 and over with mildly raised TSH but normal thyroid hormone, a year of levothyroxine lowered TSH but improved neither symptoms nor tiredness.[21]

What exercise, diet and sleep do to the signals

The circulating signals respond measurably to ordinary behaviour, but the trial effects are modest, and no trial has shown that changing these markers slows aging itself.

The big observational picture. In a UK study of 59,078 adults (median age 64) whose sleep and activity were measured with wrist sensors and who were followed for about eight years, those in the best third for sleep, activity and diet together had an estimated 9.4 more years of life expectancy, and about 9.5 more years free of five major chronic diseases, than those in the worst third. The best third slept 7.2 to 8.0 hours and did more than 42 minutes of moderate-to-vigorous activity a day. These are modelled estimates with wide margins of uncertainty, from an observational study whose senior author holds equity in a lifestyle-behaviour company.[22]

The headline figure needs stating precisely. For someone starting in the worst 5%, adding five minutes of sleep, two minutes of activity and half a serving of vegetables a day, all at once, was linked to about one extra year of life. That is a statistical extrapolation, not something measured in people who changed their habits. The three behaviours together gave a small extra boost for lifespan beyond the sum of their parts, but none for disease-free years. Those took bigger changes: about 24 more minutes of sleep, about 4 more minutes of moderate-to-vigorous activity a day and a clearly better diet were linked to roughly four extra disease-free years, with a very wide margin of uncertainty.[23]

Exercise sends signals of its own. Contracting muscle releases exerkines, signalling molecules from muscle, liver and fat, many carried in the same kind of vesicles that carry senescent cargo, with anti-inflammatory and regenerative effects on distant organs.[24] In randomised trials of structured exercise in people aged 65 and over, 8 weeks to 12 months of training produced modest falls in C-reactive protein, the standard blood marker of low-grade inflammation, while results for interleukin-6 and tumour necrosis factor alpha (TNF-alpha) were inconsistent and many trials were at risk of bias.[25] A pooling of 54 trials in about 2,800 adults aged 60 and over ranked aerobic training as giving the most consistent fall in C-reactive protein.[26] Zone 2 training and resistance training give the targets.

Diet. Across 33 randomised trials in adults, a Mediterranean pattern lowered high-sensitivity C-reactive protein and interleukin-6, though not standard C-reactive protein or TNF-alpha, and the authors call for better trials.[27] In a two-year trial of 218 healthy, non-obese adults aged 20 to 50, those assigned to cut calories by a quarter lost about 10% of their body weight and ended with C-reactive protein about 40% lower and TNF-alpha about 50% lower than the group eating normally, without weakening their vaccine responses.[28] The wider evidence on calorie restriction is under fasting.

Sleep: plausible, thinner evidence. In mice, the body clock drives a daily cycle in NAD⁺, a coenzyme cells need for repair and maintenance.[29] NAD⁺ falls with age, a changing daily rhythm is one of several suspected reasons, and falling NAD⁺ is one route by which stressed cells tip toward senescence.[30] No study has shown that short sleep lowers NAD⁺ this way in people. One small experiment links sleep loss to the senescent secretions: in 29 adults aged 61 to 86, a single night of sleep allowed only from 3 to 7 a.m. raised the activity of those secretion genes in circulating immune cells, though one senescence marker did not hold up on a confirmatory test, and only gene activity after one night was measured, not health.[31] Regular sleep that follows your body clock is sensible maintenance; see circadian rhythms.

Therapies: nothing proven for healthy adults

Two strategies aim directly at the signalling problem. Both are investigational, and several key trials were run by people with a financial stake.

Senolytics are drugs that clear senescent cells; the most studied is dasatinib plus quercetin, with fisetin close behind. The Alzheimer's pilot usually cited for "senolytics reach the brain" enrolled five people with no control group. Dasatinib reached the fluid around the brain in four of them, quercetin never did, and thinking tests and brain scans did not change. Two markers in that fluid rose, which the authors say could mean senescent cells were being cleared or simply that the drugs triggered inflammation; two of the authors hold senolytic patents.[32] A twelve-person pilot in older adults with mild memory problems and slow walking, without a control group, found no significant average change in cognition.[33] The first randomised trials are small and mixed. In 60 postmenopausal women the drug pair did not reduce the main blood marker of bone breakdown.[34] In 31 adults with scarring fatty-liver disease, about half the treated group showed less liver scarring on biopsy, against one in fourteen on placebo; side effects were more common, though all passed on their own, the authors treat the result as preliminary, and two of them have a financial interest in senolytic patents.[35]

Earlier ideas are further from the clinic. High-dose intravenous fisetin reduced senescent cells in parts of the brain in six aged sheep, a dose and route very different from an oral supplement.[36] Vaccines that train the immune system against a protein on senescent cells extended survival in male mice with a model of progeria, a genetic accelerated-aging disease,[37] and in mice fed a high-fat diet,[38] but neither study tested survival in normally aged animals, and the vaccines have never been tested in people.

Plasma exchange removes part of a person's plasma and replaces it with an albumin solution, to dilute the pro-aging factors the mouse work implicated. In a single-blind, sham-controlled trial of 42 adults over 50, assigned in order of sign-up rather than at random, the strongest schedule (exchange every two weeks plus intravenous immunoglobulin) cut estimated biological age on blood DNA-methylation clocks by about 2.6 years midway through. By the end of the study the difference from sham had disappeared, no health outcomes were measured, and several authors co-founded or belong to the company that sells the procedure; they call the trial hypothesis-generating.[39] An independent trial points the other way: in 34 healthy plasma donors aged 40 to 60, removing plasma four or eight times over 18 weeks without replacing it made no clock look younger, and three aging measures moved slightly older, possibly a stress response to the procedure.[40] The one large randomised trial against an age-related disease, in 347 people with mild-to-moderate Alzheimer's, slowed the loss of everyday abilities by about half over about 14 months, but memory and thinking scores fell just short of significance, the benefit was seen in moderate but not mild disease, and the albumin maker sponsored it.[41] Commercial "young plasma" infusions are a different thing again, with no proven benefit.

Further reading

  • López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell 2023.[42]
  • De Luca F, et al. From Senescent Cells to Systemic Inflammation: The Role of Inflammaging in Age-Related Diseases and Kidney Dysfunction. Cells 2025.[43]
  • Aamir SW, et al. Extracellular Vesicles as Key SASP Carriers Driving Cellular Senescence, Inflammaging, and Therapeutic Opportunities in Aging and Age-Related Diseases. Aging Dis 2026.[44]
  • Rebo J, Mehdipour M, Conboy MJ, Conboy IM, et al. A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood. Nat Commun 2016.[45]
  • Zhang G, Li J, Purkayastha S, et al. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature 2013 — mice.[46]
  • Veldhuis JD. Changes in pituitary function with ageing and implications for patient care. Nat Rev Endocrinol 2013.[47]
  • Koemel NA, Biswas RK, Ahmadi MN, et al. Minimum combined sleep, physical activity, and nutrition variations associated with lifeSPAN and healthSPAN improvements: a population cohort study. eClinicalMedicine 2026 — UK Biobank, n=59,078.[48]
  • Chow LS, et al. Exerkines in health, resilience and disease. Nat Rev Endocrinol 2022.[49]
  • Gonzales MM, Garbarino VR, Orr ME, et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nat Med 2023 — open-label, n=5.[50]
  • Farr JN, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med 2024 — n=60.[51]
  • Fuentealba M, Kiprov D, Verdin E, Furman D, et al. Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange. Aging Cell 2025 — n=42; author conflicts disclosed.[52]
  • Borsky P, et al. Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial). Sci Rep 2025 — n=34, no rejuvenation.[53]

— § —